September 30, 2026 Artificial intelligence is finding its way into the laboratory—and a group of biotechnology charts is giving us a reason to pay attention. The idea is straightforward: use AI to help interpret enormous amounts of biological data, identify promising drug candidates and guide experiments. Whether that produces successful medicines will take time to establish. Whether the stocks are attracting buyers is something we can examine now. This weekend, we will explore AI Meets Genomics in more depth. Today, I want to introduce the theme through a chart that deserves a place on our radar. ARKG: The broader opportunity The ARK Genomic Revolution ETF (ARKG) holds a portfolio of companies involved in genomics and related health-care innovation. It provides a way to participate across the theme while reducing dependence on the outcome of any one company’s research. That spreads company-specific risk, although the fund and its options can still be volatile. The monthly chart tells the larger story: a prolonged decline from the 2021 peak, several years of base-building, and now an advance through the descending red resistance line. Today is the final trading day of September. A close above that line would confirm the breakout on a completed monthly bar. That would be a meaningful technical development. It would not, by itself, imply a return to the old highs. The daily chart shows an established sequence of higher highs and higher lows. September’s advance cleared descending resistance near $49–$50 and carried ARKG to approximately $54.74 in this morning’s snapshot. The trend is strong, but price has moved well above the rising blue support lines. That makes entry discipline especially important. For a possible Premium addition, I am watching two developments: a daily close above the recent high near $55, or a pullback that establishes support and turns higher. A retreat below the former breakout area around $49–$50 would weaken the case. Aggressive traders: Take an initial position on a monthly close above the above shown multi-year red resistance trend line, i.e., above $52 on Sep 30, 2026 (currently, $55). January calls under consideration The January 15, 2027 $55 call is the leading candidate. This morning’s table shows a $5.40 bid and $6.10 ask, or $540–$610 per contract before fees. The spread is wide enough that a patient limit order matters. January provides roughly three and a half months for continuation. It also imposes a deadline: a favorable long-term chart does not guarantee that an option will profit before expiration. RXRX provides an individual-stock example Our acceleration screen identified Recursion Pharmaceuticals (RXRX) this morning. Recursion uses AI and laboratory data in drug discovery, and its shares are challenging a long decline. I bought its January $5 calls at $0.57 for the more aggressive setup discussed with PRO subscribers early today. ARKG offers Premium a broader way to approach the theme. Both illustrate our Confirmatory Analysis process: the business gives us a reason to investigate; the chart helps determine when to act. Premium status: ARKG—Buy Pending: Trigger = Breakout confirmed on monthly chart. If confirmed, any subsequent option entry will carry our initial −50% stop/exit rule and our established trailing-profit discipline after a 100% gain. This weekend, we’ll examine the companies, the charts and the distinction between an appealing AI story and a qualifying trade.
